U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07039201) titled 'A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC)' on March 22.
Brief Summary: This study is a single-centre, single-arm, open-label, dose-escalation exploratory study with single-dose administration. Its objective is to evaluate the safety, tolerability, dose, anti-tumor efficacy, and pharmacokinetic characteristics of CG-102-12C in the participants with GPC3-positive advanced hepatocellular carcinoma who previously received adequate but uneffective systemic standard treatments.
Study Start Date: June 20
Study Type: INTERVENTIONAL
Condition:
Advanced Hepatocellular Carcinoma (H...